<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Med. Genet</journal-id>
      <journal-title-group>
        <journal-title>BMC Medical Genetics</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2350</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25636897</article-id>
      <article-id pub-id-type="pmc">4410594</article-id>
      <article-id pub-id-type="publisher-id">144</article-id>
      <article-id pub-id-type="doi">10.1186/s12881-015-0144-7</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The rare <italic>BRAF VK600-601E</italic> mutation as a possible indicator of poor prognosis in rectal carcinoma &#x2013; a report of a case</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Mori</surname>
            <given-names>Yoshiko</given-names>
          </name>
          <address>
            <email>yoshikomori1@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Nagasaka</surname>
            <given-names>Takeshi</given-names>
          </name>
          <address>
            <email>takeshin@cc.okayama-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mishima</surname>
            <given-names>Hideyuki</given-names>
          </name>
          <address>
            <email>mishima01@sa2.so-net.ne.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Umeda</surname>
            <given-names>Yuzo</given-names>
          </name>
          <address>
            <email>y.umeda@d9.dion.ne.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Inada</surname>
            <given-names>Ryo</given-names>
          </name>
          <address>
            <email>ryo_inada@hotmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kishimoto</surname>
            <given-names>Hiroyuki</given-names>
          </name>
          <address>
            <email>kishipon777@yahoo.co.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Goel</surname>
            <given-names>Ajay</given-names>
          </name>
          <address>
            <email>ajayg@baylorhealth.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fujiwara</surname>
            <given-names>Toshiyoshi</given-names>
          </name>
          <address>
            <email>toshi_f@md.okayama-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558 Japan </aff>
        <aff id="Aff2"><label/>Cancer Center, Aichi Medical University, 1-1 Yazakokarimata, Nagakute City, Aichi 480-1195 Japan </aff>
        <aff id="Aff3"><label/>Center of Gastrointestinal Research; and Center for Epigenomics, Cancer Prevention and Cancer Genomics, Baylor Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center, 3500 Gaston Avenue, Suite H-250, Dallas, TX 75246 USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>31</day>
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>31</day>
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>16</volume>
      <elocation-id>1</elocation-id>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>10</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>7</day>
          <month>1</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Mori et al.; licensee BioMed Central. 2015</copyright-statement>
        <license license-type="open-access">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>The <italic>BRAF</italic> V600E mutation is reportedly associated with inferior survival among colon cancer patients. Here we report a patient with rectal cancer who carried the novel <italic>BRAF</italic> mutation VK600&#x2013;601E, which has analogous molecular functions to those of the conventional <italic>BRAF</italic> mutation <italic>V600E</italic>, and may have potential as a prognostic marker for colorectal cancer (CRC).</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>The present 65-year-old male patient was diagnosed with recurrent rectal adenocarcinoma (stage II by AJCC TNM staging 7th edition) 14&#xA0;months after surgery and was treated with modified FOLFOX6 (fluorouracil, leucovorin, and oxaliplatin), radiation, and FOLFIRI (fluorouracil, leucovorin, and irinotecan). The tumor progressed before further treatment could be initiated, resulting in death after 15&#xA0;months. This survival period was similar to the median overall survival among patients with metastatic CRC and <italic>BRAF</italic> mutations who were treated with the FOLFIRI regimen with or without cetuximab.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>Thus, the <italic>BRAF</italic> VK600&#x2013;601E mutation may lead to an aggressive clinical course in CRC patients suffering from rapid progression and potential resistance to multiple therapeutic modalities.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Rectal cancer</kwd>
        <kwd><italic>BRAF</italic> mutation</kwd>
        <kwd><italic>BRAF</italic> VK600-601E</kwd>
        <kwd>Chemotherapy</kwd>
        <kwd>Prognosis</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Background</title>
      <p>Prognoses for patients with colorectal cancer (CRC) have improved significantly with the introduction of molecular-targeted drugs such as anti-epidermal growth factor receptor agents (anti-EGFR). First-line treatment with the anti-EGFR cetuximab in addition to FOLFIRI (fluorouracil, leucovorin, and irinotecan) reduced the risk of progression of metastatic colorectal cancer compared with FOLFIRI treatment alone. However, the benefit of cetuximab was limited to patients with <italic>KRAS</italic> (codon 12 and 13) wild-type tumors [<xref ref-type="bibr" rid="CR1">1</xref>]. S Tejpar et al. recently reported a number of candidate markers that influence the response to anti-EGFR, even among patients with wild type <italic>KRAS</italic>, including new <italic>KRAS</italic> mutations (codon 61 and 146) and mutations in <italic>BRAF</italic> and <italic>NRAS</italic> [<xref ref-type="bibr" rid="CR2">2</xref>]. Although the best characterized <italic>KRAS</italic> mutations on codons 12 and 13 are important, other <italic>KRAS</italic> mutations, such as those on codons 61 and 146, have received recent attention.</p>
      <p>BRAF is a member of the RAF family of kinases and operates by binding to RAS [<xref ref-type="bibr" rid="CR3">3</xref>]. A recent retrospective study of several clinical trials demonstrated that the presence of the <italic>BRAF</italic> V600E mutation was a strong prognostic factor for overall survival (OS) in patients with stage II/III CRC, particularly for tumors with low or stable microsatellite instability (MSI-Low, MSI-Stable, or no MSI) [<xref ref-type="bibr" rid="CR4">4</xref>]. Activating mutations in the <italic>BRAF</italic> gene are almost within the kinase domain and produce a signaling substitution of valine for glutamic acid at position 600 (V600E) [<xref ref-type="bibr" rid="CR5">5</xref>]. However, in the present rectal cancer patient with wild-type <italic>KRAS</italic> and no MSI, we discovered a novel <italic>BRAF</italic> mutation that led to a triplet deletion of the coding nucleotides 1799&#x2013;1801 (TGA1799&#x2013;1801 deletion; VK600&#x2013;601E). This patient demonstrated relatively poor responses to conventional chemotherapy. Although this mutation has only been found in one patient to date, testing for this and other novel <italic>RAS</italic> mutations (<italic>KRAS</italic> codons 61 and 146 or <italic>NRAS</italic>) may provide essential prognostic markers that can be used to individualize treatment regimens for CRC patients.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 65-year-old man presented with perineal pain, pollakiuria, and a serum carbohydrate antigen 19&#x2013;9 level of 564.3&#xA0;IU/mL (normal, &lt;39.9&#xA0;IU/mL). He had undergone a resection without preoperative chemoradiotherapy for a 4&#x2009;&#xD7;&#x2009;4.5-cm rectal adenocarcinoma lesion 14&#xA0;months previously, which was graded as IIA (T3N0M0) according to the AJCC TNM classification [<xref ref-type="bibr" rid="CR6">6</xref>]. According to the surgical report, abdominoperineal resection with lateral lymph nodes resection and inferior mesenteric artery lymph node resection had done. Computed tomography (CT) and positron emission tomography (PET)/CT revealed a 3.5&#x2009;&#xD7;&#x2009;3.0&#x2009;&#xD7;&#x2009;2.7-cm perineal metastatic lesion obstructing the right ureter. Metastases were observed in the right obturator lymph node, and the largest lesion measured 4.0&#x2009;&#xD7;&#x2009;3.3&#x2009;&#xD7;&#x2009;3.0&#xA0;cm. The metastatic lymph node had infiltrated the right internal iliac artery (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Timeline of a rectal cancer patient with the</bold>
<bold><italic>BRAF VK600&#x2013;601E</italic></bold>
<bold>mutation.</bold> The left lower image shows the findings of the histopathological examination of the resected tumor following initial surgery in 2007, revealing a moderately to poorly differentiated adenocarcinoma. PET/CT slices show recurrent tumors; progressive perineal metastatic tumor (the white arrow) and right obturator and right internal iliac lymph node metastases (the red arrows). The tumors had infiltrated into the right internal iliac artery and right urinary duct. The perineal metastatic tumor was enlarged and had invaded the bladder (yellow arrow).</p></caption><graphic xlink:href="12881_2015_144_Fig1_HTML" id="MO1"/></fig></p>
      <p>After stent placement in the ureter, four cycles of a modified FOLFOX6 regimen (mFOLFOX6) comprising 85&#xA0;mg/m<sup>2</sup> oxaliplatin, 200&#xA0;mg/m<sup>2</sup> leucovorin, 400&#xA0;mg/m<sup>2</sup> 5-fluorouracil (5FU) bolus on day 1 and 2400&#xA0;mg/m<sup>2</sup> 5FU as a 46-h continuous infusion were administered at 2-week intervals. Subsequently, the patient experienced lower back pain, and a second PET/CT examination indicated tumor recurrence and lymph node metastases on one side of the pelvis. Chemotherapy was terminated and radiotherapy (30 fractions at 2 Gy per day; total, 60&#xA0;Gy) was initiated. Upon pain relief, mFOLFOX6 therapy was reinitiated according to the previous regimen, and no signs of disease progression were observed until 10&#xA0;months later. At this point PET/CT scans revealed that the perineal metastatic tumor had enlarged to approximately 9&#xA0;cm (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>), and the patient was hospitalized and treated with a FOLFIRI regimen comprising 150&#xA0;mg/m<sup>2</sup> irinotecan, 200&#xA0;mg/m<sup>2</sup> leucovorin, 400&#xA0;mg/m<sup>2</sup> 5FU bolus on day 1 and 2400&#xA0;mg/m<sup>2</sup> 5FU as a 46-h continuous infusion. One week later, the patient developed grade 4 neutropenia (&lt;500/mm<sup>3</sup>; Common Terminology Criteria for Adverse Events ver. 4.0).</p>
      <p>Between treatments, DNA was extracted from sections of the primary tumor tissue and analyzed for <italic>KRAS</italic> and <italic>BRAF</italic> mutations and MSI [<xref ref-type="bibr" rid="CR7">7</xref>]. No MSI or mutations at codons 12 or 13 of <italic>KRAS</italic> were identified. Direct sequencing for <italic>BRAF</italic> revealed a triplet nucleotide deletion (TGA) in coding nucleotides 1799&#x2013;1801 (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). This mutation resulted in the deletion of amino acid 601 (lysine) and a valine&#x2013;glutamate substitution at position 600 (VK600&#x2013;601E).<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold><italic>BRAF</italic></bold>
<bold>mutation analysis of the primary tumor. (a)</bold> Direct sequencing chromatographs of the <italic>BRAF VK600&#x2013;601E</italic> mutation demonstrating triplet deletion from T1799 to A1801. <bold>(b)</bold> Schematic representation of the BRAF protein structure and various mutations. CR-1, &#x2212;2, and &#x2212;3 represent conserved regions. The kinase activation segment is located between codons 594 and 623. Modified from Wan PT et al. [<xref ref-type="bibr" rid="CR12">12</xref>].</p></caption><graphic xlink:href="12881_2015_144_Fig2_HTML" id="MO2"/></fig></p>
      <p>After recovery from severe neutropenia, the perineal metastatic tumor had grown rapidly and had invaded the bladder (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>), and consequent severe hematuria and nephropyelitis resulted in renal failure. Despite therapy for renal failure, the patient died 15&#xA0;months after initiation of first-line therapy for tumor recurrence.</p>
    </sec>
    <sec id="Sec3" sec-type="conclusion">
      <title>Conclusions</title>
      <p>CRC development is considered a multistep process that follows the accumulation of genetic alterations, including chromosomal abnormalities, gene mutations, and epigenetic changes [<xref ref-type="bibr" rid="CR4">4</xref>]. The Ras&#x2013;Raf&#x2013;MAP kinase pathway is known to mediate cellular responses to extracellular signals that regulate cell proliferation, differentiation, and apoptosis [<xref ref-type="bibr" rid="CR8">8</xref>]. <italic>KRAS</italic>-activating mutations decrease or abolish the intrinsic GTPase activity of the KRAS protein, leading to its constitutive activation. Similarly, the <italic>BRAF</italic> V600E mutation induces structural changes that increase the kinase activity of the RAF protein [<xref ref-type="bibr" rid="CR9">9</xref>]. Moreover, tumors with <italic>RAS</italic> oncogene mutations are resistant to treatments with EGFR inhibitors, indicating that mutations in the <italic>RAS</italic> proto-oncogene are predictive of treatment responses [<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR10">10</xref>]. <italic>RAS</italic> mutations commonly occur in codons 12 and 13 and are implicated in many human cancers, including approximately 40% of CRC cases [<xref ref-type="bibr" rid="CR3">3</xref>]. In 2002, Davies et al. [<xref ref-type="bibr" rid="CR5">5</xref>] identified activating mutations in <italic>BRAF</italic> that were present in many human cancers, including approximately 10% of CRC cases. The <italic>BRAF</italic> V600E mutation accounts for 80% of <italic>BRAF</italic> mutations in human cancers and is thought to be biologically distinct from less frequent <italic>BRAF</italic> mutations because it allows growth in the absence of functional RAS genes [<xref ref-type="bibr" rid="CR5">5</xref>]. Interestingly, the <italic>BRAF</italic> V600E mutation has not been previously reported in combination with the <italic>KRAS</italic> mutation in patients with CRC [<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR11">11</xref>], suggesting that at least one of these pathways must remain intact for cell survival.</p>
      <p>The <italic>BRAF</italic> V600E mutation is known to be a strong prognostic marker in patients with metastatic and stage II/III CRC [<xref ref-type="bibr" rid="CR4">4</xref>]. Similar to most activating mutations, the <italic>BRAF</italic> VK600&#x2013;601E mutation affects the activation segment of BRAF. Therefore, these mutations likely disrupt the interaction between the activation segment and P-loops that normally stabilize BRAF in the inactive conformation [<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref>]. Because the <italic>BRAF</italic> VK600&#x2013;601E mutation is functionally analogous to the <italic>BRAF</italic> V600E mutation [<xref ref-type="bibr" rid="CR14">14</xref>], it may be an additional marker of recurrence and poor treatment responses in patients with CRC. In support of this hypothesis, the present CRC patient responded poorly to conventional radiotherapy and chemotherapy and died at 15&#xA0;months after initiation of first-line treatment for recurrence. This time period was almost equal to the median overall survival of patients with metastatic CRC with <italic>BRAF</italic> mutations who were treated with the FOLFIRI regimen with or without cetuximab (14.0 and 10.3&#xA0;months, respectively) [<xref ref-type="bibr" rid="CR15">15</xref>]. Although outcomes of rectal cancer often differ from those of colon cancer, clinical trials for unresectable advanced colorectal cancer always include colon and rectal cancer cases. For example, in a randomized phase III study (CRYSTAL trial) comparing FOLFIRI alone with cetuximab plus FOLFIRI regimens in 348 patients with <italic>KRAS</italic> exon2 wild-type CRCs, rectal cancer cases comprised 40.9% and 44.2% of the treatment arms, respectively [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
      <p>To our knowledge, this is the first report describing the <italic>BRAF</italic> VK600&#x2013;601E mutation in a patient with CRC. Although this mutation may be uncommon, the present observations warrant routine investigation of alternative mutations among CRC patients who show rapid progression and/or resistance to aggressive radiotherapy and/or chemotherapy.</p>
    </sec>
    <sec id="Sec4">
      <title>Consent</title>
      <p>This is a report of a case of standard treatment of the CRC with the rare somatic mutation. Written informed consent was obtained from the patient for testing the mutation status. Written informed consent for publication of this case report and accompanying images was obtained from a kin of the patient. However, we had not presented to our ethics committee, because this is not interventional study.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>YM carried out the genetic analyses and drafted the manuscript. TN treated the patient, participated in the genetic analyses and coordinated the manuscript. HM carried out the genetic analyses. YU treated the patient and collected patient&#x2019;s data. RI and HK carried out pathological staining and extracted DNA from Formalin-Fixed Paraffin-Embedded samples. AG and TF participated in the design of the study and drafted the discussion of the manuscript. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <p>The authors would like to thank Enago (<ext-link ext-link-type="uri" xlink:href="http://www.enago.jp">www.enago.jp</ext-link>) for the English language editing.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van Cutsem</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kohne</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Hitre</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Zaluski</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chang Chien</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Makhson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>D&#x2019;Haens</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pinter</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bodoky</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer</article-title>
          <source>N Engl J Med</source>
          <year>2009</year>
          <volume>360</volume>
          <issue>14</issue>
          <fpage>1408</fpage>
          <lpage>17</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa0805019</pub-id>
          <pub-id pub-id-type="pmid">19339720</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tejpar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Piessevaux</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Personalized medicine in metastatic colorectal cancer treated with anti-epidermal growth factor receptor agents: a future opportunity?</article-title>
          <source>Asia Pac J Clin Oncol</source>
          <year>2014</year>
          <volume>10</volume>
          <issue>Suppl 1</issue>
          <fpage>2</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="doi">10.1111/ajco.12176</pub-id>
          <pub-id pub-id-type="pmid">24512508</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deschoolmeester</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Baay</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Specenier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lardon</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Vermorken</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
          <article-title>A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy</article-title>
          <source>Oncologist</source>
          <year>2010</year>
          <volume>15</volume>
          <issue>7</issue>
          <fpage>699</fpage>
          <lpage>731</lpage>
          <pub-id pub-id-type="doi">10.1634/theoncologist.2010-0025</pub-id>
          <pub-id pub-id-type="pmid">20584808</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roth</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Tejpar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Delorenzi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fiocca</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Klingbiel</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Dietrich</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Biesmans</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bodoky</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Barone</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60&#x2013;00 trial</article-title>
          <source>J Clin Oncol</source>
          <year>2010</year>
          <volume>28</volume>
          <issue>3</issue>
          <fpage>466</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2009.23.3452</pub-id>
          <pub-id pub-id-type="pmid">20008640</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davies</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bignell</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stephens</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Edkins</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Clegg</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Teague</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Woffendin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Garnett</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Bottomley</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations of the BRAF gene in human cancer</article-title>
          <source>Nature</source>
          <year>2002</year>
          <volume>417</volume>
          <issue>6892</issue>
          <fpage>949</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="doi">10.1038/nature00766</pub-id>
          <pub-id pub-id-type="pmid">12068308</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Edge</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Compton</surname>
              <given-names>CC</given-names>
            </name>
          </person-group>
          <article-title>The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM</article-title>
          <source>Ann Surg Oncol</source>
          <year>2010</year>
          <volume>17</volume>
          <issue>6</issue>
          <fpage>1471</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1245/s10434-010-0985-4</pub-id>
          <pub-id pub-id-type="pmid">20180029</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nagasaka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Koi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kloor</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gebert</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vilkin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nishida</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Shin</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Sasamoto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer</article-title>
          <source>Gastroenterology</source>
          <year>2008</year>
          <volume>134</volume>
          <issue>7</issue>
          <fpage>1950</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="doi">10.1053/j.gastro.2008.02.094</pub-id>
          <pub-id pub-id-type="pmid">18435933</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peyssonnaux</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Eychene</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>The Raf/MEK/ERK pathway: new concepts of activation</article-title>
          <source>Biol Cell</source>
          <year>2001</year>
          <volume>93</volume>
          <issue>1&#x2013;2</issue>
          <fpage>53</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="doi">10.1016/S0248-4900(01)01125-X</pub-id>
          <pub-id pub-id-type="pmid">11730323</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Loupakis</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ruzzo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cremolini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Vincenzi</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Salvatore</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Santini</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Masi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Stasi</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Canestrari</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Rulli</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer</article-title>
          <source>Br J Cancer</source>
          <year>2009</year>
          <volume>101</volume>
          <issue>4</issue>
          <fpage>715</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.bjc.6605177</pub-id>
          <pub-id pub-id-type="pmid">19603018</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peeters</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Price</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Cervantes</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sobrero</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Ducreux</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hotko</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Andre</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lordick</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Punt</surname>
              <given-names>CJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer</article-title>
          <source>J Clin Oncol</source>
          <year>2010</year>
          <volume>28</volume>
          <issue>31</issue>
          <fpage>4706</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2009.27.6055</pub-id>
          <pub-id pub-id-type="pmid">20921462</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nagasaka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sasamoto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Notohara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Cullings</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Takeda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kimura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kambara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>MacPhee</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Leggett</surname>
              <given-names>BA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation</article-title>
          <source>J Clin Oncol</source>
          <year>2004</year>
          <volume>22</volume>
          <issue>22</issue>
          <fpage>4584</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2004.02.154</pub-id>
          <pub-id pub-id-type="pmid">15542810</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wan</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Garnett</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Roe</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Niculescu-Duvaz</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Good</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Springer</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Barford</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</article-title>
          <source>Cell</source>
          <year>2004</year>
          <volume>116</volume>
          <issue>6</issue>
          <fpage>855</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="doi">10.1016/S0092-8674(04)00215-6</pub-id>
          <pub-id pub-id-type="pmid">15035987</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Falco</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Giannini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tamburrino</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ugolini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lupi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Puxeddu</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Santoro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Basolo</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Functional characterization of the novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2008</year>
          <volume>93</volume>
          <issue>11</issue>
          <fpage>4398</fpage>
          <lpage>402</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2008-0887</pub-id>
          <pub-id pub-id-type="pmid">18697864</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hou</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Xing</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer</article-title>
          <source>Cell Cycle</source>
          <year>2007</year>
          <volume>6</volume>
          <issue>3</issue>
          <fpage>377</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.4161/cc.6.3.3818</pub-id>
          <pub-id pub-id-type="pmid">17297294</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van Cutsem</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kohne</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Lang</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Folprecht</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Nowacki</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Cascinu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shchepotin</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Maurel</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cunningham</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Tejpar</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status</article-title>
          <source>J Clin Oncol</source>
          <year>2011</year>
          <volume>29</volume>
          <issue>15</issue>
          <fpage>2011</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2010.33.5091</pub-id>
          <pub-id pub-id-type="pmid">21502544</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
